INFO SHEET
De-risk your immuno-oncology drug development with HUB Organoids®
![](https://resources.huborganoids.nl/hs-fs/hubfs/Assets%202022/io-drug-development.png?width=400&name=io-drug-development.png)
Immunotherapy has shown substantial success in cancer treatment, however, its efficacy is limited to only a subset of patients. Treatment failure can be attributed to the lack of predictive biomarkers, a high degree of heterogeneity in patient tumors, immunosuppressive tumor features, and the lack of clinically relevant models for preclinical testing.
Download this Infosheet to discover:
- How HUB Organoids are superior preclinical models for immunotherapy drug development
- HUB’s service offerings for CAR-T or engineered T cells, and bispecifics antibodies testing
- Our Immuno-oncology biobanks including matched normal/tumor organoids and immune cells
- Our established immune cell and tumor organoid co-cultures
![contact us](https://no-cache.hubspot.com/cta/default/14556940/5d334160-9d14-491d-a26c-e970807c8938.png)